Abstract
Monoclonal antibodies have found wide applications in the treatment of cancer, as well as of autoimmune, infectious, and other diseases. Several dozen new antibodies are currently undergoing different stages of clinical trials, and some of them will soon be added to the list of immunotherapeutic drugs. Most of these antibodies have been generated using hybridoma technology or a phage display. In recent years, new methods of obtaining human monoclonal antibodies have been actively developing. These methods rely on sequencing immunoglobulin genes from B lymphocytes, as well as on the creation of antibody-secreting stable B-cell lines. The term next-generation antibody-discovery platforms has already been established in the literature to refer to these approaches. Our review focuses on describing the results obtained by these methods.
Article PDF
Similar content being viewed by others
Abbreviations
- ELISpot:
-
enzyme-linked immunospot
- NGS:
-
next-generation sequencing
- VH:
-
variable domain of the heavy chain
- VL:
-
variable domain of the light chain
- mAb:
-
monoclonal antibody
- SARS:
-
severe acute respiratory syndrome.
References
Köhler G., Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256, 495–497.
Green L.L. 1999. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods. 231, 11–23.
Frenzel A., Schirrmann T., Hust M. 2016. Phage display-derived human antibodies in clinical development and therapy. MAbs. 8, 1177–11194.
Chiu H.Y., Wang T.S., Chan C.C., et al. 2015. Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in Chinese patients with psoriasis. Acta Dermatol. Venereol. 95, 711–716.
van Schouwenburg P.A., Rispens T., Wolbink G.J. 2013. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 9, 164–172.
Hardiman G. 2012. Next-generation antibody discovery platforms. Proc. Natl. Acad. Sci. U. S. A. 109, 18245–18246.
Lavinder J.J., Horton A.P., Georgiou G., et al. 2015. Next-generation sequencing and protein mass spectrometry for the comprehensive analysis of human cellular and serum antibody repertoires. Curr. Opin. Chem. Biol. 24, 112–120.
Galson J.D., Pollard A.J., Truck J., et al. 2014. Studying the antibody repertoire after vaccination: Practical applications. Trends Immunol. 35, 319–331.
Reddy S.T., Ge X., Miklos A.E., et al. 2010. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat. Biotechnol. 28, 965–969.
Lees W.D., Shepherd A.J. 2015. Utilities for highthroughput analysis of B-cell clonal lneages. J. Immunol. Res. 2015, 323–506.
Lebedin M.Y., Turchaninova M.A., Egorov E.S., et al. 2017. High-throughput immunoglobulin sequencing data analysis with the use of unique molecular identifiers. Immunologiya. 38, 59–63.
Turchaninova M.A., Davydov A., Britanova O.V., et al. 2016. High-quality full-length immunoglobulin profiling with unique molecular barcoding. Nat. Protoc. 11, 1599–1616.
Lu D.R., Tan Y.C., Kongpachith S., et al. 2014. Identifying functional anti-Staphylococcus aureus antibodies by sequencing antibody repertoires of patient plasmablasts. Clin. Immunol. 152, 77–89.
Wu X., Zhou T., Zhu J., Zhang B., et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 333, 1593–1602.
Wardemann H., Yurasov S., Schaefer A., et al. 2003. Predominant autoantibody production by early human B cell precursors. Science. 301, 1374–1377.
Clargo A.M., Hudson A.R., Ndlovu W., et al. 2014. The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method. MAbs. 6, 143–159.
Corti D., Voss J., Gamblin S.J., Codoni G., et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 333, 850–856.
Yu X., Tsibane T., McGraw P.A., House F.S., et al. 2008. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature. 455, 532–536.
Traggiai E., Becker S., Subbarao K., Kolesnikova L., et al. 2004. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat. Med. 10, 871–875.
Scheid J.F., Mouquet H., Feldhahn N., et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 458, 636–640.
Wrammert J., Smith K., Miller J., et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 453, 667–671.
Smith K., Garman L., Wrammert J., et al. 2009. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4, 372–384.
Tiller T., Meffre E., Yurasov S., et al. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods. 329, 112–124.
Liao H.X., Levesque M.C., Nagel A., et al. 2009. Highthroughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods. 158, 171–179.
Lin Z., Chiang N.Y., Chai N., et al. 2014. In vivo antigen-driven plasmablast enrichment in combination with antigen-specific cell sorting to facilitate the isolation of rare monoclonal antibodies from human B cells. Nat. Protoc. 9, 1563–1577.
Nakamura G., Chai N., Park S., et al. 2013. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe. 14, 93–103.
Tan Y.C., Blum L.K., Kongpachith S., et al. 2014. High-throughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination. Clin. Immunol. 151, 55–65.
DeKosky B.J., Ippolito G.C., Deschner R.P., et al. 2013. High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat. Biotechnol. 31, 166–169.
Wine Y., Boutz D.R., Lavinder J.J., et al. 2013. Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response. Proc. Natl. Acad. Sci. U. S. A. 110, 2993–2998.
Cheung W.C., Beausoleil S.A., Zhang X., et al. 2012. A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat. Biotechnol. 30, 447–452.
Aman P., Ehlin-Henriksson B., Klein G. 1984. Epstein–Barr virus susceptibility of normal human B lymphocyte populations. J. Exp. Med. 159, 208–220.
Crain M.J., Sanders S.K., Butler J.L., et al. 1989. Epstein–Barr virus preferentially induces proliferation of primed B cells. J. Immunol. 143, 1543–1548.
Laffly E., Sodoyer R. 2005. Monoclonal and recombinant antibodies, 30 years after. Hum. Antibodies. 14, 33–55.
Stahli C., Staehelin T., Miggiano V., et al. 1980. High frequencies of antigen-specific hybridomas: Dependence on immunization parameters and prediction by spleen cell analysis. J. Immunol. Methods. 32, 297–304.
Banchereau J., Bazan F., Blanchard D., et al. 1994. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12, 881–922.
Banchereau J., Rousset F. 1991. Growing human B lymphocytes in the CD40 system. Nature. 353, 678–679.
O’Nions J., Allday M.J. 2004. Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein–Barr virus or T cell-derived mitogens. J. Gen. Virol. 85, 881–895.
Wiesner M., Zentz C., Mayr C., et al. 2008. Conditional immortalization of human B cells by CD40 ligation. PLoS ONE. 3, e1464.
Kwakkenbos M.J., Diehl S.A., Yasuda E., et al. 2010. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123–128.
Kwakkenbos M.J., van Helden P.M., Beaumont T., et al. 2016. Stable long-term cultures of self-renewing B cells and their applications. Immunol. Rev. 270, 65–77.
Kwakkenbos M.J., Bakker A.Q., van Helden P.M., et al. 2014. Genetic manipulation of B cells for the isolation of rare therapeutic antibodies from the human repertoire. Methods. 65, 38–43.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © A.A. Lushova, M.G. Biazrova, A.G. Prilipov, G.K. Sadykova, T.A. Kopylov, A.V. Filatov, 2017, published in Molekulyarnaya Biologiya, 2017, Vol. 51, No. 6, pp. 899–906.
Rights and permissions
About this article
Cite this article
Lushova, A.A., Biazrova, M.G., Prilipov, A.G. et al. Next-Generation Techniques for Discovering Human Monoclonal Antibodies. Mol Biol 51, 782–787 (2017). https://doi.org/10.1134/S0026893317060103
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893317060103